SLIL has a pipeline of more than a dozen human health Lead Compounds, the first of which is schedule to enter a human clinical trial for AIDS-related lymphoma in 2003. SLIL’s drug discovery program is focused on three streams of research: Polyamine analogs: Compounds that mimic natural polyamines and have great therapeutic potential Cyclic polyamines: a new class of cytotoxic agents originally derived from plant alkyloids TTD™: Tumor Targeting and Delivery technologies: drug delivery technologies that are designed to concentrate anti-cancer drugs at the site of a tumor